Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Analgesic Efficacy and Safety of Oral CMX-020 in Subjects with Symptoms of Sciatica Resulting from Lumbosacral Radiculopathy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs CMX 020 (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors Cmxtwenty
- 14 Oct 2016 Status changed from recruiting to completed.
- 01 Oct 2015 New trial record